Analysis of topoisomerase mutations in fluoroquinolone-resistant and -susceptible Campylobacter jejuni strains isolated in Senegal

Int J Antimicrob Agents. 2007 Apr;29(4):397-401. doi: 10.1016/j.ijantimicag.2006.11.012. Epub 2007 Jan 16.

Abstract

In this study, topoisomerase mutations in ciprofloxacin-resistant and -susceptible Campylobacter jejuni were analysed by DNA sequencing. In certain ciprofloxacin-resistant C. jejuni, the mechanism of resistance was complex. The Thr86-Ala substitution in the GyrA protein appears to play a role in increasing the minimum inhibitory concentration of nalidixic acid only. In addition, isolates with this amino acid change and those resistant to quinolones but lacking a mutation in the GyrA quinolone resistance-determining region could be derived from two different clones. Based on gyrA and gyrB polymorphisms, C. jejuni isolates from the Dakar region of Senegal appeared to be less diverse than those from other countries. Moreover, C. jejuni isolates in Senegal appeared to differ from European isolates by lack of a silent mutation at codon 120 of the gyrA gene.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Campylobacter Infections / drug therapy
  • Campylobacter Infections / epidemiology
  • Campylobacter Infections / microbiology
  • Campylobacter jejuni / drug effects*
  • Campylobacter jejuni / genetics*
  • DNA Gyrase / drug effects
  • DNA Gyrase / genetics*
  • DNA Topoisomerase IV / drug effects
  • DNA Topoisomerase IV / genetics
  • Drug Resistance, Bacterial / genetics*
  • Europe
  • Fluoroquinolones / pharmacology*
  • Microbial Sensitivity Tests
  • Mutation
  • Nalidixic Acid / pharmacology
  • Polymorphism, Genetic
  • Senegal / epidemiology

Substances

  • Fluoroquinolones
  • Nalidixic Acid
  • DNA Topoisomerase IV
  • DNA Gyrase